StreetInsider.com News Articles

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:05:00 -0400

NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a per share exercise price of $13.07.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:05:00 -0400

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics to Present at September Investor Conferences

Wed, 26 Aug 2026 08:05:00 -0400

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.

Key Details:

Citi's 2026 Biopharma Back to School Conference (New York, NY)
Date/Time: Wednesday, September 9, 2026, at 10:00AM ET
Webcast Link: Citi / Candel Fireside

Candel Therapeutics to Present at September Investor Conferences

Wed, 26 Aug 2026 08:05:00 -0400

Key Details:

Citi's 2026 Biopharma Back to School Conference (New York, NY)
Date/Time: Wednesday, September 9, 2026, at 10:00AM ET
Webcast Link: Citi / Candel Fireside

Form 4 Candel Therapeutics, For: Aug 17 Filed by: Tyagarajan Seshu

Wed, 19 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26950495.html

Form 4 Candel Therapeutics, For: Aug 17 Filed by: Tyagarajan Seshu

Wed, 19 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260819/26950495.html

Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu

Mon, 17 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26938467.html

Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu

Mon, 17 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260817/26938467.html

Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker

Mon, 17 Aug 2026 12:22:54 -0400

Freedom Broker analyst Ilya Zubkov raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $15.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "The key event of the quarter was the start of patient enrollment in the global registrational Phase III AURORA trial of CAN-2409 in NSCLC, alongside the publication of pivotal Phase III data that strengthened our confidence in the drug's approval potential. The company confirmed plans to file a BLA for CAN-2409 in localized prostate cancer in Q4'26 and continues to guide to a potential commercial launch in 2027. Operating expenses came in above our

Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker

Mon, 17 Aug 2026 12:22:54 -0400

Freedom Broker analyst Ilya Zubkov raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $15.00 (from $14.00) while maintaining a Buy rating.

Candel Therapeutics Inc. (CADL) PT Raised to $12 at BofA Securities

Fri, 14 Aug 2026 05:18:58 -0400

BofA Securities analyst Alec Stranahan raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $12.00 (from $9.00) while maintaining a Neutral rating.

Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c

Thu, 13 Aug 2026 08:58:17 -0400

Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q2 EPS of ($0.52), $0.29 worse than the analyst estimate of ($0.23).

For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.

Form 10-Q Candel Therapeutics, For: Jun 30

Thu, 13 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26917112.html

Form 10-Q Candel Therapeutics, For: Jun 30

Thu, 13 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26917112.html

Form 8-K Candel Therapeutics, For: Aug 13

Thu, 13 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916971.html

Form 8-K Candel Therapeutics, For: Aug 13

Thu, 13 Aug 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260813/26916971.html

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 08:05:00 -0400

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026
Pivotal phase 3 clinical data published in The Lancet Oncology demonstrated a statistically significant improvement in disease-free survival with aglatimagene plus standard-of-care radiotherapy compared with radiotherapy alone in patients with localized, intermediate- to high-risk prostate cancer
Presented supportive clinical data from extended follow-up of the phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer in a plenary oral presentation at the American Urological Association (AUA) 2026 Annual

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 08:05:00 -0400

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026

Pivotal phase 3 clinical data published in The Lancet Oncology demonstrated a statistically significant improvement in disease-free survival with aglatimagene plus standard-of-care radiotherapy compared with radiotherapy alone in patients with localized, intermediate- to high-risk prostate cancer

Presented supportive clinical data from extended follow-up of the phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer in a plenary oral presentation at the American Urological Association (AUA) 2026 Annual

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:05:00 -0400

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company’s common stock, with a per share exercise price of $10.01.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 16:05:00 -0400

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company’s common stock, with a per share exercise price of $10.01.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics to present prostate cancer data at ASTRO 2026

Mon, 03 Aug 2026 08:05:13 -0400

Candel Therapeutics, Inc. (Nasdaq: CADL) announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, scheduled for September 26-30, 2026, in Boston.

The presentation, titled "Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer," will feature data from the company's Phase 3 trial of aglatimagene besadenovec in localized prostate cancer. Francesca Barone, MD, PhD, Chief Scientific Officer at Candel Therapeutics, is scheduled to present the poster on September 29, 2026, from 2:15 PM to 3:30 PM ET at the Thomas M. Menino Convention and Exhibition Center.

Candel

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Mon, 03 Aug 2026 08:05:00 -0400

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA.

Aglatimagene besadenovec – Localized Prostate Cancer

Abstract Title: Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer
Presenter: Francesca

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

Mon, 03 Aug 2026 08:05:00 -0400

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA.

Aglatimagene besadenovec – Localized Prostate Cancer

Abstract Title: Quantitative Digital Pathology Defines Immune Activation Following Aglatimagene Besadenovec Immunotherapy in Localized Prostate Cancer
Presenter: Francesca

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Wed, 29 Jul 2026 08:05:00 -0400

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present at Canaccord Genuity’s 46th Annual Growth Conference, taking place August 11-13, 2026, in Boston, MA.

Presentation Details:
Date: Wednesday, August 12, 2026
Time: 12 PM EDT
Webcast Link: Canaccord Genuity / Candel Presentation

A webcast of the presentation will be available by selecting Events and Presentations in the Investors section

Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

Wed, 29 Jul 2026 08:05:00 -0400

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present at Canaccord Genuity’s 46th Annual Growth Conference, taking place August 11-13, 2026, in Boston, MA.

Presentation Details:
Date: Wednesday, August 12, 2026
Time: 12 PM EDT
Webcast Link: Canaccord Genuity / Candel Presentation

A webcast of the presentation will be available by selecting Events and Presentations in the Investors section